Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on OTC Pharma Packaging

Posted by Matt Breese on Feb 13, 2018

As the U.S. reported sales of $45.8 billion for over-the-counter (OTC) medicine in 2016, manufacturing and packaging firms saw great opportunity to capitalize in the space, according to Pharmapack. 
 
To seize the opportunity, OTC makers need to understand the changing market dynamics: growing health care costs, aging populations, demand for more affordable health care and increasing M&A activity.  
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on IVIG (Feb 2018)

Posted by Matt Breese on Feb 9, 2018

According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for Product Launch

Posted by Matt Breese on Feb 8, 2018

When launching new products, pharmaceutical companies should bring an outcome rather than just a product to market, according to a new study from the professional services company Accenture.

Findings from the study, titled "Product Launch: The Patient Has Spoken," suggest that a medication's benefits are the key factors patients consider when looking at new products. More than 69% of patients think the benefits are more important than the brand of the product. 

Read More

Topics: Product Release, Branding & Marketing

Perspectives on Triggered Messages

Posted by Matt Breese on Feb 6, 2018

Data is nothing new to pharmaceutical marketers, who have become accustomed to using data to generate triggered messages, a near-real-time reaction to certain events or decisions, to their providers.
 
The next step is to go beyond simple messaging and personally tailor the message across varied platforms by using analytics and predictive tools, says Jose Ferreira, vice president of customer experience and data management at CMI/Compas. 
 
Read More

Topics: Data & Analytics, Branding & Marketing

MMIT Reality Check on HIV (Feb 2018)

Posted by Matt Breese on Feb 2, 2018

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on PCSK9 Inhibitors (Jan 2018)

Posted by Matt Breese on Jan 31, 2018

According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on Cystic Fibrosis (Jan 2018)

Posted by Matt Breese on Jan 23, 2018

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

MMIT Reality Check on Growth Hormones (Jan 2018)

Posted by Matt Breese on Jan 8, 2018

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Data & Analytics, Branding & Marketing

Perspectives on Drug Naming Policies

Posted by Matt Breese on Jan 2, 2018

When it comes time to name your pharmaceutical brand asset, there are important regulations to keep in mind. Gaining approval on a product name can impact your ability to stay on track for a product launch timeline. 
 
In 2017, the FDA published an industry guide on the Nonproprietary Naming of Biological Products. This guide is an excellent resource for pharma leaders.
 
Read More

Topics: Branding & Marketing

MMIT Reality Check on Diabetes (Dec 2017)

Posted by Matt Breese on Dec 31, 2017

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing